KPV
Anti-inflammatory · By Preptide Pro editorial team · Last updated
KPV is a anti-inflammatory peptide, and it is not FDA-approved. A tripeptide fragment of alpha-melanocyte-stimulating hormone. Studied in lab and animal models of inflammation, particularly in the gut.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 125672 |
|---|---|
| CAS number | 67727-97-3 |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.43 g/mol |
| Other names | Lys-pro-val, L-Lysyl-L-prolyl-L-valine, Msh (11-13), RefChem:159939, alpha-Msh (11-13), L-Valine, N-(1-L-lysyl-L-prolyl)-, a-MSH (11-13) (free acid), Lysyl-prolyl-valine |
Is KPV FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on KPV?
PubMed lists 37 records for “KPV tripeptide OR "lysine-proline-valine"”, of which 0 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. | Tissue Cell | 2026 Oct 7 |
| KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. | Tissue Cell | 2026 Aug 9 |
| Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. | Cytotechnology | 2026 Jun |
| NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development. | Cell Death Differ | 2026 Feb |
| Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. | Int J Med Sci | 2025 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.